Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Trovagene, Quest in acute myelogenous leukemia marker license agreement

Trovagene has provided license to Quest Diagnostics to use its nucleophosmin protein (NPM1) into research and clinical testing services related to acute myelogenous leukemia.

Trovagene holds a license to US patent 8,222,370 and the corresponding group of US and foreign patent applications around NPM.

Trovagene chief technology officer Charlie Rodi said the company continues to expand patient access to the NPM1 marker.

"Physicians need accurate tools to assess prognosis, select therapies and evaluate for bone marrow transplant," Rodi added.

"Use of this marker can help physicians more effectively treat patients with AML."